246 results about "Virulence factor" patented technology

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as B. anthracis, S. aureus, and P. aeruginosa.

Methods and systems for identification of microorganisms either after isolation from a culture or directly from a sample. The methods and systems are configured to identify microorganisms based on the characterization of proteins of the microorganisms via high-resolution/mass accuracy single-stage (MS) or multi-stage (MSⁿ) mass spectrometry. Included herein are also discussion of targeted detection and evaluation of virulence factors, antibiotic resistance markers, antibiotic susceptibility markers, typing, or other characteristics using a method applicable to substantially all microorganisms and high-resolution/mass accuracy single-stage (MS) or multi-stage (MSⁿ) mass spectrometry.

Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also methods for using the antigenically enhanced bacteria are also disclosed, as well as vaccines containing the enteric bacteria. Specifically a whole enteric bacterium or components thereof are provided by Helicobacter species. Also there are other enteric bacteria which are useful for the disclosed invention; such as Campylobacter jejuni.

The invention discloses a primer system for detecting 10 common pathogenic bacteria of clinical infection. The detection system is used for detecting blood or body fluid (pleural fluid, ascitic fluid,drainage fluid, synovial fluid and cerebrospinal fluid) infected samples of patients infected by the pathogenic bacteria; detection results are combined with other clinical indicators, reference canbe provided for early diagnosis for clinicians and rational use of antibiotics, and treatment delaying and nonstandard use of the antibiotics are avoided. Virulence factor gene loci of 10 differentpathogenic bacteria can be simultaneously detected in two reaction systems; compared with sequencing, real-time fluorescence quantitative PCR and other technologies, the cost is lower, the operation is more convenient, and the accuracy and sensitivity are improved.

The invention discloses attenuated, brightened and replication-controllable HSV recombinant virus, a preparation method and applications thereof. According to the present invention, thymidine kinase (TK) gene essential for replicating viruses in neurons and being a main virulence factor is knocked out by using a homologous recombination method, and subsequently a red or green fluorescent gene enhancement expression cassette is recombined into the genome of the virus to construct a series of novel recombinants viruses, wherein the toxicity is markedly low, the states of infected mice are good,the fluorescence signal is strong, and the expression of the recombinant viruses is limited at the injection site after the recombinant viruses are used in in-vivo animal center labeling; by combiningwith Cre-dependent AAV helper viruses capable of expressing TK in a compensated manner, the cell-specific transmonosynaptic loop tracing is achieved; and the recombinant HSV has wide application value in nervous system targeted gene transduction, neural network transsynaptic tracing, tumor disintegration, viral replication and pathogenesis mechanism, antiviral drug screening and other fields.

One aspect of the present invention is directed to a composition. The composition includes a dispersion inducer comprising:

H₃C—(CH₂)_n—CH_mCH_mR,

where is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid. The composition additionally contains an additive component selected from one or more of the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. The composition is formulated so that when it is contacted with a biofilm produced by a microorganism, where the biofilm comprises a matrix and microorganism on a surface, the dispersion inducer selectively acts on the microorganism and has a suitable biological response without a required direct effect on the matrix to disperse the biofilm. The present invention is also directed to methods of using this compound.

The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.

The invention discloses a multiple PCR detection kit for virulence factors of streptococcus suis and a detection method thereof, and belongs to the technical field of biology. The multiple PCR detection kit comprises nucleic acid shown by base sequences, such as SEQ ID NO:1 to SEQ ID NO:20. The detection method for the multiple PCR detection kit comprises the following steps of: 1, providing DNA of samples to be detected; 2, taking the kit, amplifying the DNA of the samples to be detected by adopting the conventional PCR method, detecting an amplified result by adopting an agarose gel electrophoresis method, and judging according to the result; and by using positive DNA of streptococcus suis 2 type as contrast, if the contrast proves that not all the strips are amplified, re-detecting, and if the contrast proves that all the strips are amplified, judging the result. The multiple PCR detection method established by the invention is specific and sensitive, and has the advantages of simpleness, convenience and quickness. The multiple PCR detection kit has reliable stability, and can be used for rapid detection of clinical samples and survey research on molecular epidemiology for the streptococcus suis.

The invention provides a helicobacter pylori tetravalent virulence factor multi-epitope vaccine and a preparation method thereof. The active constituent of the vaccine is polypeptide. The vaccine mainly comprises the dominant Th and B cell epitopes or sections of a urease A subunit, a urease B subunit, cytotoxin associated protein A and vacuolating cytotoxin associated protein A, and neutrophil activating protein. The gene synthesis and molecular cloning technology is used for building a fused gene containing the dominant Th and B cell epitopes or sections of ureases, the cytotoxin associated protein A and the vacuolating cytotoxin associated protein A, and the neutrophil activating protein. Escherichia coli is used for expressing the fused gene, and the tetravalent virulence factor multi-epitope vaccine is obtained after protein purification. The vaccine can stimulate a body to generate T cell immunity response and specific antibody humoral immunity response aiming at the ureases, the cytotoxin associated protein A, the vacuolating cytotoxin associated protein A and the neutrophil activating protein and can be used for preventing and treating diseases related to helicobacter pylori infection.

The invention relates to a Brucella vaccine, in particular to the molecular marker and virulence gene deletion of Brucella vaccine strain. The study uses luciferase modified gene (Luc NF plus) to replace the partial fragment of Bp26 gene of Brucella attenuated vaccine S19 strain by constructing suicide plasmid and adopting the method of targeted homologous recombination (gene targeting), so as to damage the expression of the immunogenicity protein BP26 and construct the gene deletion mutant strain Delta S19-1 of the Brucella Bp26. The BMP18 protein is one of the main virulence factors of Brucella. The invention adopts the same method to exclude the Bmp 18 gene of Delta S19-1, so as to lead the Delta S19-1 not to express the Bmp 18 protein and the Brucella virulence gene deletion mutant strain Delta S19-2 is constructed. The invention solves the problems that the conventional Brucella vaccine can not distinguish between the artificial immunization and the wild bacteria infection of people and animals, the virus is strong and the vaccine is easy to cause the illness of inoculated people and animals. The invention has important significance and practical application value of the monitoring, diagnosis, purification and all the controls of Brucella.

Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.

The present invention is directed to novel nucleotide sequences to be used for diagnosis, identification of the strain, typing of the strain and giving orientation to its potential degree of virulence, infectivity and/or latency for all infectious diseases more particularly tuberculosis. The present invention also includes method for the identification and selection of polymorphisms associated with the virulence' and /or infectivity in infectious diseases more particularly in tuberculosis by a comparative genomic analysis of the sequences of different clinical isolates/strains of infectious organisms. The regions of polymorphisms, can also act as potential drug targets and vaccine targets.; More particularly, the invention also relates to identifying virulence factors of M. tuberculosis strains and other infectious organisms to be included in a diagnostic DNA chip allowing identification of the strain, typing of the strain and finally giving orientation to its potential degree of virulence. Although the present invention has been illustrated with specific reference to the polymorphic region in the Mycobacterium tuberculosis, the said invention is not to be understood and construed as being limited to Tuberculosis but is applicable to all infectious diseases.

The invention relates to a bovine-derived single-chain antibody for resisting a staphylococcus aureus LukD virulence factor and preparation and application thereof, and specifically comprises the bovine-derived single-chain antibody for resisting the staphylococcus aureus LukD virulence factor, a carrier and a host cell for screening the single-chain antibody, a preparation method of the single-chain antibody and application of the single-chain antibody. The prokaryotic expression single-chain antibody at least comprises a light chain variable region with an amino acid sequence shown as SEQ ID No.1, a heavy chain variable region with an amino acid sequence shown as SEQ ID No.2 and an intermediate connecting peptide located between the light chain variable region and the heavy chain variable region. Compared with the prior art, the bovine-derived single-chain antibody for resisting the staphylococcus aureus LukD virulence factor can be specifically combined with staphylococcus aureus LukD protein and inhibit the membrane lysis effect of LukED on bovine mammary epithelial cells, so that the adhesion and damage of staphylococcus aureus to the bovine mammary epithelial cells are weakened, and the bovine-derived single-chain antibody has a certain function of inhibiting the damage of staphylococcus aureus to mammary gland.

The present application relates to immunogenic compositions comprising a mixture of Bordetella (e.g., B. pertussis) antigens and an oil in water nanoemulsion. In particular, the invention provides immunogenic compositions comprising nanoemulsion and a combination of Bordetella (e.g., B. pertussis) antigens that have different functions, for example, combinations including B. pertussis adherence factors (adhesins), B. pertussis toxins or B. pertussis virulence factors. Vaccines, methods of treatment, uses of and processes to make a pertussis or whooping cough vaccine are also described. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

The invention relates to a fish vaccine and a preparation method thereof, in particular to an aeromonas hydrophila inactivated vaccine and the preparation thereof. The aeromonas hydrophila inactivatedvaccine is prepared by the following concrete steps: separating out a pathogen from a sick fish, determining the pathogen as an aeromonas hydrophila through morphology, virulence factors, biochemicalreaction and gene sequencing; rejuvenating the strain, selecting an optimum condition for cultivation; then selecting the optimum condition for inactivation to prepare the aeromonas hydrophila inactivated vaccine, and conforming the aeromonas hydrophila inactivated vaccine to be certificated through sterility test and security test. The inactivated vaccine is prepared from a pathogenic bacterialstrain separated from a sick fish body, has a simple operating method, strong pertinency, strong protective function, good immunological effect and low cost of the used material, and is suitable for mass production. The invention provides a practical method for preventing and curing the bacteremic septicemia of carps.

The invention provides Muricauda olearia. Muricauda oleariah is a quorum sensing quenching strain capable of inhibiting the secretion of pathogenic bacteria virulence factors, and the preservation number of Muricauda olearia LMM001 strain is CGMCC No. 8972. The invention also provides an AHL degrading enzyme MomL protein separated from the LMM001 strain, wherein the amino acid sequence of the MomL protein is SEQ ID NO: 1. The Muricauda olearia LMM001 strain disclosed by the invention can block the QS pathway of pathogenic bacteria by small molecule QS repressor, AHL lactonase MomL, AHL acyltransferase and other ways, and reduce the secretion of pathogenic bacteria virulence factors; the LMM001 strain has no toxic and side effects on zebrafish and can improve the resistance of zebrafish to the infection of Aeromonas hydrophila; AHL lactonase can greatly reduce the secretion of virulence factors such as Pseudomonas aeruginosa extracellular protease and pyocyanine and can reduce the synthesis of Chromobacterium violaceum and violacein.

The invention discloses application of 1,3,4-thiadiazole compounds to prevention and treatment of rice xanthomonas oryzae. The structural general formula of the compounds is as shown in the formula I.The compounds with the general formula have remarkable inhibiting effects on the activity of an hpa1 promoter. Part of the compounds has a remarkable inhibiting effect on a key virulence factor T3SSunder the condition of not influencing the normal growth of the rice xanthomonas oryzae, so the 1,3,4-thiadiazole compounds can be applied to prevention and treatment of the rice xanthomonas oryzae well.

The invention relates to the technical field of medicine, and provides application of luteolin in a bacterial quorum sensing inhibition system, application of luteolin in preparing drug for lowering pathogenicity of staphylococcus aureus virulence factors and application of luteolin in preparing drug for inhibiting transcription of hla and agrA genes of staphylococcus aureus. Minimum effective concentration with application value is provided for the application of luteolin in the bacterial quorum sensing inhibition system, and a reference is provided for medically preparing specific bio-film forming inhibitors. The invention further provides a drug combination for inhibiting formation of staphylococcus aureus bio-films. The drug combination contains luteolin. According to the drug combination, formation of the bio-films of staphylococcus aureus can be inhibited by effectively inhibiting a quorum sensing system of staphylococcus aureus through tiny luteolin, prognosis risk, of staphylococcus aureus, for infection with high-drug-tolerance bio-films in anti-infection treatment is lowered, and a valuable reference is provided for medically preparing specific preparations for inhibiting the staphylococcus aureus bio-films.

Screening procedures are disclosed for identifying compounds useful for inhibiting fungal infection or pathogenicity. Methods are also disclosed for identifying fungal pathogenic virulence factors.